Radionuclide Molecular Imaging of EpCAM Expression in Triple-Negative Breast Cancer Using the Scaffold Protein DARPin Ec1

Bibliografski detalji
Parent link:Molecules
Vol. 25, iss. 20.— 2020.— [4719, 20 p.]
Autori kompanije: Национальный исследовательский Томский политехнический университет Исследовательская школа химических и биомедицинских технологий, Национальный исследовательский Томский политехнический университет Исследовательская школа химических и биомедицинских технологий Научно-исследовательский центр "Онкотераностика"
Daljnji autori: Vorobjeva (Vorobyeva) A. G. Anzhelika Grigorjevna, Bezverkhniaia E. A. Ekaterina Aleksandrovna, Konovalova E. V. Elena Valerjevna, Shulga (Schulga) A. A. Aleksey Anatolievich, Garousi Ja. Javad, Vorontsova O. Olga, Abouzayed A. Ayman, Orlova A. M. Anna Markovna, Deev S. M. Sergey Mikhaylovich, Tolmachev V. M. Vladimir Maksimilianovich
Sažetak:Title screen
Efficient treatment of disseminated triple-negative breast cancer (TNBC) remains an unmet clinical need. The epithelial cell adhesion molecule (EpCAM) is often overexpressed on the surface of TNBC cells, which makes EpCAM a potential therapeutic target. Radionuclide molecular imaging of EpCAM expression might permit selection of patients for EpCAM-targeting therapies. In this study, we evaluated a scaffold protein, designed ankyrin repeat protein (DARPin) Ec1, for imaging of EpCAM in TNBC. DARPin Ec1 was labeled with a non-residualizing [125I]I-para-iodobenzoate (PIB) label and a residualizing [99mTc]Tc(CO)3 label. Both imaging probes retained high binding specificity and affinity to EpCAM-expressing MDA-MB-468 TNBC cells after labeling. Internalization studies showed that Ec1 was retained on the surface of MDA-MB-468 cells to a high degree up to 24 h. Biodistribution in Balb/c nu/nu mice bearing MDA-MB-468 xenografts demonstrated specific uptake of both [125I]I-PIB-Ec1 and [99mTc]Tc(CO)3-Ec1 in TNBC tumors. [125I]I-PIB-Ec1 had appreciably lower uptake in normal organs compared with [99mTc]Tc(CO)3-Ec1, which resulted in significantly (p < 0.05) higher tumor-to-organ ratios. The biodistribution data were confirmed by micro-Single-Photon Emission Computed Tomography/Computed Tomography (microSPECT/CT) imaging. In conclusion, an indirectly radioiodinated Ec1 is the preferable probe for imaging of EpCAM in TNBC.
Jezik:engleski
Izdano: 2020
Teme:
Online pristup:https://doi.org/10.3390/molecules25204719
Format: Elektronički Poglavlje knjige
KOHA link:https://koha.lib.tpu.ru/cgi-bin/koha/opac-detail.pl?biblionumber=664643

MARC

LEADER 00000naa0a2200000 4500
001 664643
005 20251117110340.0
035 |a (RuTPU)RU\TPU\network\35827 
035 |a RU\TPU\network\35534 
090 |a 664643 
100 |a 20210512d2020 k||y0rusy50 ba 
101 0 |a eng 
102 |a CH 
135 |a drcn ---uucaa 
181 0 |a i  
182 0 |a b 
200 1 |a Radionuclide Molecular Imaging of EpCAM Expression in Triple-Negative Breast Cancer Using the Scaffold Protein DARPin Ec1  |f A. G. Vorobjeva (Vorobyeva), E. A. Bezverkhniaia, E. V. Konovalova [et al.] 
203 |a Text  |c electronic 
300 |a Title screen 
320 |a [References: 52 tit.] 
330 |a Efficient treatment of disseminated triple-negative breast cancer (TNBC) remains an unmet clinical need. The epithelial cell adhesion molecule (EpCAM) is often overexpressed on the surface of TNBC cells, which makes EpCAM a potential therapeutic target. Radionuclide molecular imaging of EpCAM expression might permit selection of patients for EpCAM-targeting therapies. In this study, we evaluated a scaffold protein, designed ankyrin repeat protein (DARPin) Ec1, for imaging of EpCAM in TNBC. DARPin Ec1 was labeled with a non-residualizing [125I]I-para-iodobenzoate (PIB) label and a residualizing [99mTc]Tc(CO)3 label. Both imaging probes retained high binding specificity and affinity to EpCAM-expressing MDA-MB-468 TNBC cells after labeling. Internalization studies showed that Ec1 was retained on the surface of MDA-MB-468 cells to a high degree up to 24 h. Biodistribution in Balb/c nu/nu mice bearing MDA-MB-468 xenografts demonstrated specific uptake of both [125I]I-PIB-Ec1 and [99mTc]Tc(CO)3-Ec1 in TNBC tumors. [125I]I-PIB-Ec1 had appreciably lower uptake in normal organs compared with [99mTc]Tc(CO)3-Ec1, which resulted in significantly (p < 0.05) higher tumor-to-organ ratios. The biodistribution data were confirmed by micro-Single-Photon Emission Computed Tomography/Computed Tomography (microSPECT/CT) imaging. In conclusion, an indirectly radioiodinated Ec1 is the preferable probe for imaging of EpCAM in TNBC. 
461 |t Molecules 
463 |t Vol. 25, iss. 20  |v [4719, 20 p.]  |d 2020 
610 1 |a электронный ресурс 
610 1 |a труды учёных ТПУ 
610 1 |a EpCAM 
610 1 |a radionuclide 
610 1 |a molecular imaging 
610 1 |a SPECT 
610 1 |a iodine 
610 1 |a PIB 
610 1 |a breast 
610 1 |a cancer 
610 1 |a радионуклиды 
610 1 |a визуализация 
701 1 |a Vorobjeva (Vorobyeva)  |b A. G.  |c specialist in the field of medical technology  |c Senior Researcher, Oncoteranostika Research Center, Tomsk Polytechnic University, Ph.D  |f 1990-  |g Anzhelika Grigorjevna  |3 (RuTPU)RU\TPU\pers\46556  |9 22214 
701 1 |a Bezverkhniaia  |b E. A.  |c pharmacist  |c Research Engineer Tomsk Polytechnic University  |f 1994-  |g Ekaterina Aleksandrovna  |3 (RuTPU)RU\TPU\pers\46845  |9 22467 
701 1 |a Konovalova  |b E. V.  |c specialist in the field of chemical technology and biotechnology  |c engineer at Tomsk Polytechnic University  |f 1985-  |g Elena Valerjevna  |9 88562 
701 1 |a Shulga (Schulga)  |b A. A.  |c biologist  |c Researcher, Tomsk Polytechnic University, Candidate of Biological Sciences  |f 1960-  |g Aleksey Anatolievich  |3 (RuTPU)RU\TPU\pers\46796  |9 22432 
701 1 |a Garousi  |b Ja.  |g Javad 
701 1 |a Vorontsova  |b O.  |g Olga 
701 1 |a Abouzayed  |b A.  |g Ayman 
701 1 |a Orlova  |b A. M.  |c specialist in the field of medical technology  |c Senior Researcher, Oncoteranostika Research Center, Tomsk Polytechnic University, Ph.D  |f 1960-  |g Anna Markovna  |3 (RuTPU)RU\TPU\pers\46554  |9 22212 
701 1 |a Deev  |b S. M.  |c biologist  |c Leading Researcher, Tomsk Polytechnic University, Doctor of Biological Sciences  |f 1951-  |g Sergey Mikhaylovich  |3 (RuTPU)RU\TPU\pers\39299  |9 20959 
701 1 |a Tolmachev  |b V. M.  |c specialist in the field of medical technology  |c Director of the Research Center "Oncoteranostika", Tomsk Polytechnic University, Ph.D  |f 1961-  |g Vladimir Maksimilianovich  |3 (RuTPU)RU\TPU\pers\46552  |9 22210 
712 0 2 |a Национальный исследовательский Томский политехнический университет  |b Исследовательская школа химических и биомедицинских технологий  |c (2017- )  |3 (RuTPU)RU\TPU\col\23537 
712 0 2 |a Национальный исследовательский Томский политехнический университет  |b Исследовательская школа химических и биомедицинских технологий  |b Научно-исследовательский центр "Онкотераностика"  |3 (RuTPU)RU\TPU\col\27561 
801 2 |a RU  |b 63413507  |c 20210512  |g RCR 
856 4 |u https://doi.org/10.3390/molecules25204719 
942 |c CF